These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 35737669)
21. Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. Kasaian J; Mosaffa F; Behravan J; Masullo M; Piacente S; Ghandadi M; Iranshahi M Fitoterapia; 2015 Jun; 103():149-54. PubMed ID: 25843566 [TBL] [Abstract][Full Text] [Related]
22. Reversal effects of Rabdosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro. Li F; Fan J; Wu Z; Liu RY; Guo L; Dong Z; Wang Z Pharm Biol; 2013 Sep; 51(9):1196-203. PubMed ID: 23777360 [TBL] [Abstract][Full Text] [Related]
23. 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer. Zhang E; Liu J; Shi L; Guo X; Liang Z; Zuo J; Xu H; Wang H; Shu X; Huang S; Zhang S; Kang X; Zhen Y Life Sci; 2019 Dec; 238():116938. PubMed ID: 31593704 [TBL] [Abstract][Full Text] [Related]
24. Barbigerone reverses multidrug resistance in breast MCF-7/ADR cells. Li X; Wan L; Wang F; Pei H; Zheng L; Wu W; Ye H; Wang Y; Chen L Phytother Res; 2018 Apr; 32(4):733-740. PubMed ID: 29368443 [TBL] [Abstract][Full Text] [Related]
25. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway. Huang Q; Wu YY; Xing SJ; Yu ZW Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380 [TBL] [Abstract][Full Text] [Related]
27. Shenmai injection suppresses multidrug resistance in MCF-7/ADR cells through the MAPK/NF-κB signalling pathway. Yang L; Zhang C; Chen J; Zhang S; Pan G; Xin Y; Lin L; You Z Pharm Biol; 2020 Dec; 58(1):276-285. PubMed ID: 32251615 [No Abstract] [Full Text] [Related]
28. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-activity relationship of lipo-diterpenoid alkaloids with potential target of topoisomerase IIα for breast cancer treatment. Luan S; Gao Y; Liang X; Zhang L; Yin L; He C; Liu S; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B Bioorg Chem; 2021 Apr; 109():104699. PubMed ID: 33611138 [TBL] [Abstract][Full Text] [Related]
30. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells. Hu D; Li M; Su J; Miao K; Qiu X Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260 [TBL] [Abstract][Full Text] [Related]
31. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride. Chen YY; Li ZZ; Ye YY; Xu F; Niu RJ; Zhang HC; Zhang YJ; Liu YB; Han BS BMC Mol Biol; 2016 Mar; 17():6. PubMed ID: 26935744 [TBL] [Abstract][Full Text] [Related]
32. Artemisinin-indole and artemisinin-imidazole hybrids: Synthesis, cytotoxic evaluation and reversal effects on multidrug resistance in MCF-7/ADR cells. Hu Y; Li N; Zhang J; Wang Y; Chen L; Sun J Bioorg Med Chem Lett; 2019 May; 29(9):1138-1142. PubMed ID: 30837097 [TBL] [Abstract][Full Text] [Related]
33. A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells. Xue P; Yang X; Liu Y; Xiong C; Ruan J Biomed Pharmacother; 2014 Oct; 68(8):1049-56. PubMed ID: 25455158 [TBL] [Abstract][Full Text] [Related]
34. Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15. Ballaré C; Portela P; Schiaffi J; Yomha R; Mordoh J Breast Cancer Res Treat; 1998 Jan; 47(2):163-70. PubMed ID: 9497104 [TBL] [Abstract][Full Text] [Related]
35. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
36. Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin. Luan S; Zhong H; Zhao X; Yang J; Jing Y; Liu D; Zhao L Eur J Med Chem; 2017 Dec; 141():584-595. PubMed ID: 29102180 [TBL] [Abstract][Full Text] [Related]
37. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway. Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474 [TBL] [Abstract][Full Text] [Related]
38. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. Tsou SH; Chen TM; Hsiao HT; Chen YH PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866 [TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. Tang X; Gu X; Ai H; Wang G; Peng H; Lai Y; Zhang Y Bioorg Med Chem Lett; 2012 Jan; 22(2):801-5. PubMed ID: 22209486 [TBL] [Abstract][Full Text] [Related]
40. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]